Aurobindo Pharma Ltd (NSE:AUROPHARMA)
₹ 1227.4 41.7 (3.52%) Market Cap: 719.18 Bil Enterprise Value: 719.74 Bil PE Ratio: 21.89 PB Ratio: 2.33 GF Score: 92/100

Q1 2022 Aurobindo Pharma Ltd Earnings Call Transcript

Aug 13, 2021 / 03:00AM GMT
Release Date Price: ₹761.3 (-7.86%)
Operator

Ladies and gentlemen, good day, and welcome to the Aurobindo's Pharma Q1 FY '22 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Arvind Bothra, Investor Relations. Thanks, and over to you, sir.

Arvind Bothra
Aurobindo Pharma Limited - Head of IR & Corporate Communications

Thank you. Good morning, and a warm welcome to our first quarter FY '22 earnings call. I am Arvind Bothra from the Investor Relations team, Aurobindo Pharma Limited. We hope you have received the Q1 FY '22 financials and the press release that we sent out yesterday. The same is also available on our website.

With me, we have our senior management team represented by Mr. P.V. Ramprasad Reddy, Chairman, Aurobindo Pharma USA; Mr. N. Govindarajan, Managing Director, Aurobindo Pharma Limited; Mr. Sanjeev Dani, COO and Head, Formulations; Mr. Santhanam Subramanian, CFO; and Mr. Swami Iyer, CFO, Aurobindo Pharma USA. We will begin the call with summary highlights from the management followed by an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot